BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 336 filers reported holding BIO-TECHNE CORP in Q3 2019. The put-call ratio across all filers is 5.05 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,756,954 | -13.3% | 128,658 | +3.6% | 0.02% | -10.5% |
| Q2 2023 | $10,104,229 | +16.9% | 124,244 | +6.4% | 0.02% | +11.8% |
| Q1 2023 | $8,643,293 | -13.1% | 116,759 | -2.4% | 0.02% | -15.0% |
| Q4 2022 | $9,942,610 | +4.9% | 119,643 | +258.5% | 0.02% | -4.8% |
| Q3 2022 | $9,480,000 | -24.7% | 33,375 | -8.1% | 0.02% | -19.2% |
| Q2 2022 | $12,591,000 | -22.4% | 36,311 | -2.9% | 0.03% | -7.1% |
| Q1 2022 | $16,221,000 | -26.3% | 37,381 | -12.3% | 0.03% | -20.0% |
| Q4 2021 | $21,995,000 | +10.8% | 42,601 | +4.1% | 0.04% | +2.9% |
| Q3 2021 | $19,859,000 | +13.1% | 40,933 | +4.9% | 0.03% | +17.2% |
| Q2 2021 | $17,554,000 | +43.1% | 39,005 | +21.3% | 0.03% | +31.8% |
| Q1 2021 | $12,271,000 | -1.9% | 32,156 | -18.4% | 0.02% | -12.0% |
| Q4 2020 | $12,506,000 | +5.5% | 39,396 | -17.7% | 0.02% | -3.8% |
| Q3 2020 | $11,850,000 | +11.5% | 47,848 | +18.8% | 0.03% | +8.3% |
| Q2 2020 | $10,632,000 | +53.4% | 40,272 | +10.1% | 0.02% | +33.3% |
| Q1 2020 | $6,933,000 | -16.1% | 36,575 | -2.8% | 0.02% | +20.0% |
| Q4 2019 | $8,261,000 | +24.2% | 37,640 | +10.8% | 0.02% | +15.4% |
| Q3 2019 | $6,650,000 | -8.3% | 33,983 | -2.3% | 0.01% | -7.1% |
| Q2 2019 | $7,255,000 | -0.4% | 34,797 | -5.1% | 0.01% | +7.7% |
| Q1 2019 | $7,282,000 | +34.0% | 36,672 | -2.4% | 0.01% | +8.3% |
| Q4 2018 | $5,436,000 | -58.1% | 37,561 | -41.0% | 0.01% | -52.0% |
| Q3 2018 | $12,986,000 | -3.4% | 63,625 | -30.0% | 0.02% | -10.7% |
| Q2 2018 | $13,445,000 | -7.4% | 90,871 | -5.5% | 0.03% | +12.0% |
| Q1 2018 | $14,514,000 | -7.9% | 96,128 | -21.5% | 0.02% | -3.8% |
| Q4 2017 | $15,763,000 | +9.6% | 122,424 | +2.9% | 0.03% | +4.0% |
| Q3 2017 | $14,376,000 | -7.4% | 118,920 | -10.0% | 0.02% | -10.7% |
| Q2 2017 | $15,532,000 | +19.8% | 132,191 | +3.7% | 0.03% | +16.7% |
| Q1 2017 | $12,962,000 | +9.5% | 127,512 | +11.5% | 0.02% | +4.3% |
| Q4 2016 | $11,836,000 | – | 114,395 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |